Evidence map›Paper›PMID 41756849›Full record

ArticlebioRxiv : the preprint server for biology2026

Caroline D Doherty, Sonia Jain, Lauren L Ott, Katie K Bakken, Brandon A Wilbanks, Danielle M Burgenske, Keenan S Pearson, Jessica I Griffith, Zichen Tian, Jeffrey A Meridew and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Updated by
    2026
5 · Who and what money

Authors and funding

14 authors.

Caroline D Doherty
Sonia Jain
Lauren L Ott
Katie K Bakken
Brandon A WilbanksORCID 0000-0002-1583-023X
Danielle M Burgenske
Keenan S Pearson
Jessica I Griffith
Zichen Tian
Jeffrey A Meridew
Saigopalakrishna S Yerneni
William F Elmquist
Jann N Sarkaria

Funding

DNA aptamers as tools for toxin delivery to glioblastomaF30CA294722 · NCI · MAYO CLINIC ROCHESTER · PI Caroline Diane Doherty · 2025 to 2026
$105k
NCI NIH HHS F30 CA294722
6 · The paper itself

Abstract

Glioblastoma (GBM) is an aggressive, high-grade glioma with a near-universally fatal prognosis. Therapeutic failure is often attributed to the highly selective blood brain barrier (BBB), the diffuse infiltrative nature of the tumor, and the marked intratumoral heterogeneity of GBM. Although antibody drug conjugates ADCs have shown promise for high grade gliomas such as GBM, efficacy is limited by ADC size. Aptamers-short, synthetic, single-stranded DNA or RNA molecules-can be ∼6-fold lower in molecular weight than IgG antibodies and have the potential to cross the intact BBB. Unlike other nucleic acid-based therapies, aptamer function arises from three-dimensional shape rather than genetic coding. Here we aim to replace the targeting component of the ADC paradigm with a DNA aptamer, thus creating an aptamer-drug conjugate (ApDC). We employed

Identifiers

PMID41756849
PMCPMC12934727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.